CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
-8.73%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$2.56B
AUM Growth
+$2.56B
(-26%)
Cap. Flow
-$400M
Cap. Flow
% of AUM
-15.58%
Top 10 Holdings %
Top 10 Hldgs %
43.81%
Holding
134
New
13
Increased
7
Reduced
67
Closed
28
Top Buys
| 1 |
Monte Rosa Therapeutics
GLUE
|
$69.6M |
| 2 |
Biomea Fusion
BMEA
|
$48.4M |
| 3 |
AMAM
Ambrx Biopharma, Inc. Common Stock
AMAM
|
$47M |
| 4 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$44.6M |
| 5 |
VERV
Verve Therapeutics
VERV
|
$40.6M |
Top Sells
| 1 |
C4 Therapeutics
CCCC
|
$80.8M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$64.2M |
| 3 |
Novavax
NVAX
|
$45.3M |
| 4 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$43.6M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$32.8M |
Sector Composition
| 1 | Healthcare | 99.14% |
| 2 | Financials | 0.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
TPTX
1
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $237M | 8.05% | 3,037,042 +287,042 | +10% | +$22.4M |
|
2
Atea Pharmaceuticals
AVIR
$267M
| $138M | 4.68% | 6,411,355 | – | – |
|
|
FMTX
3
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $118M | 3.99% | 4,721,589 +1,589 | +0% | +$39.6K |
|
4
BridgeBio Pharma
BBIO
$9.89B
| $115M | 3.9% | 1,880,980 -287,929 | -13% | -$17.6M |
|
5
Design Therapeutics
DSGN
$315M
| $106M | 3.6% | 5,414,850 +300,000 | +6% | +$5.87M |
|
6
Revolution Medicines
RVMD
$7.1B
| $106M | 3.6% | 3,338,166 +813,166 | +32% | +$25.8M |
|
7
Olema Pharmaceuticals
OLMA
$375M
| $86M | 2.92% | 3,073,485 -122,059 | -4% | -$3.42M |
|
8
BioAtla
BCAB
$26.7M
| $82.7M | 2.81% | 1,951,718 -240,342 | -11% | -$10.2M |
|
|
9
Monte Rosa Therapeutics
GLUE
$296M
| $69.6M | 2.36% | +3,193,973 | New | +$69.6M |
|
10
Edgewise Therapeutics
EWTX
$1.51B
| $66.5M | 2.26% | 3,140,914 +800,000 | +34% | +$16.9M |
|
11
Avidity Biosciences
RNA
$5.99B
| $55.1M | 1.87% | 2,228,667 -235,878 | -10% | -$5.83M |
|
|
12
Apellis Pharmaceuticals
APLS
$3.48B
| $53.7M | 1.82% | 850,000 -1,016,108 | -54% | -$64.2M |
|
13
ALX Oncology
ALXO
$62.7M
| $48.6M | 1.65% | 889,454 +7,684 | +0.9% | +$420K |
|
|
14
Biomea Fusion
BMEA
$116M
| $48.4M | 1.65% | +3,170,872 | New | +$48.4M |
|
|
AMAM
15
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $47M | 1.6% | +2,486,386 | New | +$47M |
|
16
Zymeworks
ZYME
$1.12B
| $45.9M | 1.56% | 1,321,936 -678,064 | -34% | -$23.5M |
|
|
JBIO
17
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $44.6M | 1.52% | +2,030,691 | New | +$44.6M |
|
|
RXDX
18
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $44.5M | 1.51% | 1,848,024 -250,000 | -12% | -$6.02M |
|
19
Tarsus Pharmaceuticals
TARS
$2.47B
| $43.9M | 1.49% | 1,514,269 -200,000 | -12% | -$5.8M |
|
20
Stoke Therapeutics
STOK
$1.08B
| $43M | 1.46% | 1,278,276 -159,531 | -11% | -$5.37M |
|
21
Rocket Pharmaceuticals
RCKT
$354M
| $42.9M | 1.46% | 968,550 -400,000 | -29% | -$17.7M |
|
|
VERV
22
DELISTED
Verve Therapeutics
VERV
| $40.6M | 1.38% | +709,224 | New | +$40.6M |
|
|
RAIN
23
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $39.7M | 1.35% | +2,626,660 | New | +$39.7M |
|
24
Aclaris Therapeutics
ACRS
$209M
| $35.1M | 1.19% | 2,000,000 | – | – |
|
|
CNTA
25
Centessa Pharmaceuticals
CNTA
$2.25B
| $31.1M | 1.05% | +1,427,273 | New | +$31.1M |
|